Latest news with #TheNasdaqGlobalMarket
Yahoo
3 days ago
- Business
- Yahoo
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, June 02, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today announced that on June 2, 2025, the Compensation Committee of Zentalis' Board of Directors granted non-qualified stock options to purchase an aggregate of 137,400 shares of the Company's common stock to four (4) newly hired employees. The stock options were granted under the Zentalis Pharmaceuticals, Inc. 2022 Employment Inducement Incentive Award Plan (2022 Inducement Plan) as an inducement material to each such individual's entering into employment with Zentalis in accordance with Nasdaq Listing Rule 5635(c)(4). The 2022 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Zentalis, or following a bona fide period of non-employment, as an inducement material to each such individual's entering into employment with Zentalis, pursuant to Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price of $1.28 per share, which is equal to the closing price of Zentalis' common stock on The Nasdaq Global Market on the date of grant. The stock options have a 10-year term and will vest over four years, with 25% of the options vesting on the first anniversary of the vesting commencement date and the remaining 75% of the options vesting in equal monthly installments over the three years thereafter. Vesting of the stock options is subject to the employees' continued service to Zentalis on each vesting date. About Zentalis PharmaceuticalsZentalis® Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1+ platinum-resistant ovarian cancer (PROC). Azenosertib is being evaluated as a monotherapy and in combination across multiple tumor types in clinical trials and has broad franchise potential. In clinical trials, azenosertib has been well tolerated and has demonstrated anti-tumor activity as a single agent across multiple tumor types. The Company is also leveraging its extensive experience and capabilities to translate its science to advance research on additional areas of opportunity for azenosertib outside PROC. Zentalis has operations in San Diego. For more information, please visit Follow Zentalis on X/Twitter at @ZentalisP and on LinkedIn at Contact:Aron Feingold, VP, IR & Corp Commsir@
Business Wire
4 days ago
- Business
- Business Wire
Berto Acquisition Corp. Announces the Separate Trading of its Ordinary Shares and Warrants, Commencing on or about June 5, 2025
NEW YORK--(BUSINESS WIRE)--Berto Acquisition Corp. (Nasdaq: TACOU) (the 'Company'), the ninth special purpose acquisition company sponsored by Harry You, today announced that, commencing on or about June 5, 2025, holders of the units sold in the Company's initial public offering completed on May 1, 2025 (the 'offering'), may elect to separately trade the ordinary shares and warrants included in the units. No fractional warrants will be issued upon separation of the units and only whole warrants will trade. The ordinary shares and warrants that are separated will trade on The Nasdaq Global Market under the symbols 'TACO' and 'TACOW,' respectively, and those units not separated will continue to trade under the symbol 'TACOU.' Holders of units will need to have their brokers contact Continental Stock Transfer & Trust Company, the Company's transfer agent, in order to separate the units into ordinary shares and warrants. A registration statement relating to these securities was declared effective by the U.S. Securities and Exchange Commission (the 'SEC') on April 29, 2025. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About Berto Acquisition Corp. Berto Acquisition Corp., which is led by Executive Chairman and Interim Chief Financial Officer Harry You, is a blank check company incorporated as a Cayman Islands exempted company whose business purpose is to effect a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The Company may pursue an acquisition opportunity in any industry or sector, and intends to capitalize on the ability of its management team to identify and combine with a business or businesses that can benefit from the management team's established relationships and operating experience. While its focus is broad because of management's perspective on technology, quantum computing and other growth industries, having looked at over a thousand acquisition targets over the past decade, it will be examining in particular, opportunities in artificial intelligence as well as in the rapidly growing wellness, longevity and aesthetics areas. Cautionary Note Concerning Forward-Looking Statements This press release contains statements that constitute 'forward-looking statements,' including with respect to the Company's search for an initial business combination. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company's registration statement and final prospectus for the Company's offering filed with the SEC. Copies are available on the SEC's website, The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.
Yahoo
4 days ago
- Business
- Yahoo
Berto Acquisition Corp. Announces the Separate Trading of its Ordinary Shares and Warrants, Commencing on or about June 5, 2025
NEW YORK, June 02, 2025--(BUSINESS WIRE)--Berto Acquisition Corp. (Nasdaq: TACOU) (the "Company"), the ninth special purpose acquisition company sponsored by Harry You, today announced that, commencing on or about June 5, 2025, holders of the units sold in the Company's initial public offering completed on May 1, 2025 (the "offering"), may elect to separately trade the ordinary shares and warrants included in the units. No fractional warrants will be issued upon separation of the units and only whole warrants will trade. The ordinary shares and warrants that are separated will trade on The Nasdaq Global Market under the symbols "TACO" and "TACOW," respectively, and those units not separated will continue to trade under the symbol "TACOU." Holders of units will need to have their brokers contact Continental Stock Transfer & Trust Company, the Company's transfer agent, in order to separate the units into ordinary shares and warrants. A registration statement relating to these securities was declared effective by the U.S. Securities and Exchange Commission (the "SEC") on April 29, 2025. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About Berto Acquisition Corp. Berto Acquisition Corp., which is led by Executive Chairman and Interim Chief Financial Officer Harry You, is a blank check company incorporated as a Cayman Islands exempted company whose business purpose is to effect a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The Company may pursue an acquisition opportunity in any industry or sector, and intends to capitalize on the ability of its management team to identify and combine with a business or businesses that can benefit from the management team's established relationships and operating experience. While its focus is broad because of management's perspective on technology, quantum computing and other growth industries, having looked at over a thousand acquisition targets over the past decade, it will be examining in particular, opportunities in artificial intelligence as well as in the rapidly growing wellness, longevity and aesthetics areas. Cautionary Note Concerning Forward-Looking Statements This press release contains statements that constitute "forward-looking statements," including with respect to the Company's search for an initial business combination. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company's registration statement and final prospectus for the Company's offering filed with the SEC. Copies are available on the SEC's website, The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law. View source version on Contacts Harry YouExecutive Chairman, Interim Chief Financial OfficerBerto Acquisition Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Insider
6 days ago
- Business
- Business Insider
ContextLogic to commence trading on OTC markets, delist from Nasdaq
ContextLogic (LOGC) announced its intention to voluntarily delist from The Nasdaq Global Market at the close of markets on June 2, 2025 and to begin trading on the OTCQB Venture Market of the OTC Markets on June 3, 2025. The company is pleased to announce that the company has been accepted for listing on the OTCQB Venture Market of the OTC Markets and that the company's Class A Common Stock will commence trading on the OTC Markets on Tuesday, June 3, 2025 under the ticker symbol 'LOGC'. Shareholders will not be required to exchange their share certificates or take any other action in connection with the OTC Markets listing as there will be no change in the trading symbol or CUSIP for the Common Stock. The company also announces that as a result of its listing on the OTC Markets, it intends to voluntarily delist its Common Stock from The Nasdaq Global Market and file a Form 25 with the U.S. SEC on or about June 9, 2025. As a result, the company anticipates that the delisting of its Common Stock from Nasdaq will become effective 10 days after the filing, unless otherwise directed by Nasdaq. Confident Investing Starts Here:
Yahoo
29-05-2025
- Business
- Yahoo
Titan Acquisition Corp Announces the Separate Trading of its Class A Ordinary Shares and Warrants, Commencing on or about June 2, 2025
BROOKLYN, N.Y., May 29, 2025 (GLOBE NEWSWIRE) -- Titan Acquisition Corp (Nasdaq: TACHU) (the 'Company') announced that holders of the units sold in the Company's initial public offering of 27,600,000 units, which includes 3,600,000 units issued pursuant to the exercise by the underwriters of their overallotment option, completed on April 10, 2025 (the 'Offering') may elect to separately trade the Class A ordinary shares and warrants included in the units commencing on or about June 2, 2025. Any units not separated will continue to trade on The Nasdaq Global Market under the symbol 'TACHU', and each of the Class A ordinary shares and warrants will separately trade on The Nasdaq Global Market under the symbols 'TACH' and 'TACHW,' respectively. No fractional warrants will be issued upon separation of the units and only whole warrants will trade. Holders of units will need to have their brokers contact Continental Stock Transfer & Trust Company, the Company's transfer agent, in order to separate the units into Class A ordinary shares and warrants. The Company is a blank check company incorporated as an exempted company under the laws of the Cayman Islands, which will seek to effect a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities. A registration statement relating to the securities was declared effective on April 8, 2025, in accordance with Section 8(a) of the Securities Act of 1933, as amended. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Cautionary Note Concerning Forward-Looking Statements This press release contains statements that constitute 'forward-looking statements,' including with respect to the Company's search for an initial business combination. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company's registration statement for the initial public offering filed with the SEC. Copies are available on the SEC's website, The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law. Contact Titan Acquisition CorpMr. Adeel RoufChief Financial Officer, President and Director131 Concord StreetBrooklyn, NY 11201Email: adeel@
